<p>On June 21, according to the Novo Nordisk website, at the American Diabetes Association scientific meeting held in Chicago, Novo Nordisk announced the results of the Phase 3b STEPUP trial for patients with obesity who do not have diabetes. The data showed that during the 72-week treatment period, a higher dose of Wegovy® led to an average weight loss of 21% in obese patients compared to the placebo, with one-third of participants achieving a weight loss of 25% or more. The safety and tolerability of the higher dose of Wegovy were consistent with the 2.4mg dose</p>

<p>Novo Nordisk announced the results of the Phase 3b STEPUP trial at the American Diabetes Association scientific meeting, showing that a higher dose of Wegovy® led to an average weight loss of 21% in non-diabetic obese patients over 72 weeks. One-third of the participants lost 25% or more of their body weight, and the safety and tolerability of this dose were consistent with the 2.4mg dose</p>

Zhitong

Novo Nordisk AS

Novo Nordisk AS announced the latest research results on semaglutide: higher doses of Wegovy can lead to an average weight loss of 21% for patients with obesity